Novozymes A/S B

CPSE:NSISB

丹麥 / 材料 / 化學品

綜觀

股息

10年歷史財務資料

股價

405.00 DKK


Key Metrics	Latest
Total Revenue	3.833 B
Adjusted EBITDA	1.082 B
EBITDA Margin	28.2%
Net Profit Margin	14.6%
Total Assets	15.196 B
Total Debt	1.797 B

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months

Revenue	1,876	1,902	1,952	1,927	1,924	1,883	2,009	2,360	2,402	3,834	3,834
% Growth		1.4%	2.6%	-1.3%	-0.2%	-2.1%	6.7%	17.5%	1.8%	59.6%

Adjusted EBITDA	665	663	683	683	613	631	680	769	757	1,082	1,082
% Margin	35.5%	34.8%	35.0%	35.4%	31.9%	33.5%	33.9%	32.6%	31.5%	28.2%	28.2%

Adjusted EBIT	542	539	553	557	480	492	523	602	611	843	843
% Margin	28.9%	28.3%	28.4%	28.9%	25.0%	26.1%	26.0%	25.5%	25.4%	22.0%	22.0%

Adjusted Net Income	396	414	440	440	378	382	409	436	465	559	559
% Margin	21.1%	21.8%	22.6%	22.8%	19.7%	20.3%	20.3%	18.5%	19.4%	14.6%	14.6%

Adjusted Basic EPS	1.29	1.38	1.49	1.51	1.33	1.36	1.47	1.58	1.68	2.01	2.01

支援算式

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Original
EUR	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	1,876	1,902	1,952	1,927	1,924	1,883	2,009	2,360	2,402	3,834	3,834
% Growth	NA	1.4%	2.6%	-1.3%	-0.2%	-2.1%	6.7%	17.5%	1.8%	59.6%

Cost of Revenue	(764)	(804)	(820)	(816)	(855)	(828)	(848)	(1,071)	(1,097)	(1,840)	(1,840)
Gross Profit	1,113	1,098	1,132	1,112	1,069	1,055	1,161	1,289	1,305	1,993	1,993
% Revenue	59.3%	57.7%	58.0%	57.7%	55.6%	56.0%	57.8%	54.6%	54.3%	52.0%	52.0%

Research and Development	(254)	(251)	(257)	(250)	(263)	(260)	(270)	(269)	(271)	(413)	(413)
Selling and Marketing	(211)	(218)	(217)	(208)	(218)	(209)	(260)	(305)	(317)	(551)	(551)
General and Admin	(119)	(107)	(114)	(105)	(111)	(100)	(120)	(125)	(129)	(215)	(215)
Other Inc / (Exp)	(40)	3	(20)	(22)	31	(6)	28	33	(57)	(317)	(317)
Total Operating Exp	(624)	(573)	(609)	(584)	(561)	(575)	(622)	(666)	(774)	(1,496)	(1,496)

Operating Income	489	526	523	528	508	480	539	624	531	498	498
% Revenue	26.1%	27.6%	26.8%	27.4%	26.4%	25.5%	26.8%	26.4%	22.1%	13.0%	13.0%

Interest Expense	(4)	(3)	(3)	(0)	1	(7)	(11)	(11)	(7)	(80)	(80)
Pre-tax Income	485	522	521	527	508	473	527	613	525	417	417
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	(107)	(112)	(102)	(95)	(86)	(93)	(105)	(117)	(117)	(111)	(111)
Net Income to Company	379	410	419	432	422	380	423	496	408	306	306
% Margin	20.2%	21.6%	21.5%	22.4%	21.9%	20.2%	21.0%	21.0%	17.0%	8.0%	8.0%

Minority Interest in Earnings	(0)	0	(0)	(0)	(0)	(0)	0	(1)	(2)	0	0
Net Income to Stockholders	378	410	419	432	422	380	423	494	406	306	306

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0	0	0	0

Net Income to Common	378	410	419	432	422	380	423	494	406	306	306
% Margin	20.2%	21.6%	21.5%	22.4%	21.9%	20.2%	21.0%	20.9%	16.9%	8.0%	8.0%

As Reported
Basic EPS (Continuing Ops)	1.24	1.37	1.42	1.49	1.48	1.35	1.52	1.79	1.47	1.10	1.10
Diluted EPS (Continuing Ops)	1.22	1.35	1.41	1.48	1.47	1.35	1.51	1.77	1.46	1.10	1.10

WA Basic Shares Out.	306.00	300.47	295.34	290.42	285.11	280.43	277.92	276.64	276.12	277.90	277.90
WA Diluted Shares Out.	309.37	303.12	297.20	292.36	286.55	282.02	280.23	278.73	277.90	277.90	277.90

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	485	522	521	527	508	473	527	613	525	417	417
Addback: Net Interest Expense	4	3	3	0	(1)	7	11	11	7	80	80
Addback: Other Non Operating Expenses, Total	30	8	1	19	32	9	4	59	2	4	4
Addback: Depreciation & Amortization	124	124	130	126	133	139	157	167	146	239	239
Addback: Restructuring Charges	0	0	0	0	0	0	0	0	0	35	35
Addback: Merger / Acquisition Expenses	0	0	0	0	0	4	0	9	73	298	298
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	16	0	0	0	0	(63)	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	9	0	(26)	(6)	(16)	0	0	0	0
Addback: Asset Writedown	23	5	4	10	6	4	6	4	0	22	22
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	(40)	0	(8)	(30)	4	(13)	(13)
Adjusted EBITDA	665	663	683	683	613	631	680	769	757	1,082	1,082
% Margin	35.5%	34.8%	35.0%	35.4%	31.9%	33.5%	33.9%	32.6%	31.5%	28.2%	28.2%

Adjusted EBIT	542	539	553	557	480	492	523	602	611	843	843
% Margin	28.9%	28.3%	28.4%	28.9%	25.0%	26.1%	26.0%	25.5%	25.4%	22.0%	22.0%

Adjusted Net Income Reconciliation
Net Income to Company	379	410	419	432	422	380	423	496	408	306	306
Addback: Unusual Items	23	5	29	10	(60)	3	(19)	(80)	77	342	342
Less: Tax Benefit of Unusual Items (26%)	(6)	(1)	(7)	(3)	16	(1)	5	21	(20)	(89)	(89)
Adjusted Net Income	396	414	440	440	378	382	409	436	465	559	559
% Margin	21.1%	21.8%	22.6%	22.8%	19.7%	20.3%	20.3%	18.5%	19.4%	14.6%	14.6%

載入錯誤

Novozymes A/S B

CPSE:NSISB

丹麥 / 材料 / 化學品

10年歷史財務資料